Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
3 papers
Research so far paints a cautiously hopeful picture about using psilocybin to reduce anxiety. Small clinical trials and reviews show that, when psilocybin is given together with careful therapy and support, some people — especially those facing life‑threatening illness — report less anxiety for weeks or months. However, most studies are small or early stage, and scientists say we need bigger, better trials before we can be sure how well it works, who it helps, and how safe it is long term.
This paper looked across existing studies of psilocybin and found that, when it is given along with psychotherapy or therapy-style support, it looks promising as a treatment for several mental health problems, including cases that did not get better with other treatments. But the authors say the current studies are…
This review describes a rapid rise in medical research on psychedelic drugs over the past five years. Several later-stage clinical trials have been published, and many different drugs — including psilocybin, MDMA, ketamine, LSD, ayahuasca, and ibogaine — are being tested for conditions such as depression, post‑traumatic stress, addiction, obsessive‑compulsive…
Researchers reviewed the fast-growing interest in psychedelic therapies. They found that even though hundreds of studies are under way, no psychedelic medicine is officially approved for any mental health condition yet. The review explains the kinds of drugs being tested, the conditions people hope to treat, and big challenges such…
